Cargando…

Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review

BACKGROUND: Sickle cell disease (SCD) is a hemoglobinopathy with increasing global prevalence resulting in pain episodes and multiorgan complications. Complications of SCD have been shown to adversely impact health-related quality of life (HRQOL) comprised of physical, social, and emotional domains;...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Mira, Elmuti, Lena, Badawy, Sherif M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313963/ https://www.ncbi.nlm.nih.gov/pubmed/35898672 http://dx.doi.org/10.1155/2022/2122056

Ejemplares similares

Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults
por: Badawy, Sherif M., et al.
Publicado: (2017)

Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents
por: Reddy, Paavani S., et al.
Publicado: (2022)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

P1434: THE RELATIONSHIP BETWEEN MEDICATION ADHERENCE, BARRIERS TO MEDICATION ADHERENCE, AND QUALITY OF LIFE IN SICKLE CELL DISEASE
por: King, Kathryn, et al.
Publicado: (2023)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
por: Pandey, Akancha, et al.
Publicado: (2022)

Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach
por: Alberts, Nicole M, et al.
Publicado: (2020)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance
por: Mathias, Joacy G., et al.
Publicado: (2021)

Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea
por: Allard, Pierre, et al.
Publicado: (2021)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

A systematic review on hydroxyurea therapy for sickle cell disease in India
por: Pandey, Apoorva, et al.
Publicado: (2022)

Hydroxyurea: Pattern of Use, Patient Adherence, and Safety Profile in Patients with Sickle Cell Disease in Oman
por: Jose, Jimmy, et al.
Publicado: (2019)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine
por: Kilonzi, Manase, et al.
Publicado: (2022)

The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease
por: Kang, Hyeun Ah, et al.
Publicado: (2020)

Adherence to hydroxyurea, health-related quality of life domains and attitudes towards a smartphone app among Irish adolescents and young adults with sickle cell disease
por: Fogarty, Helen, et al.
Publicado: (2021)

Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
por: Green, Nancy S., et al.
Publicado: (2013)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
por: Wong, Trisha E., et al.
Publicado: (2021)

Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study
por: Badawy, Sherif M, et al.
Publicado: (2022)

Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea
por: Ward, Joel, et al.
Publicado: (2018)

Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach
por: Nazon, Charlotte, et al.
Publicado: (2019)

A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study
por: Creary, Susan, et al.
Publicado: (2019)

The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis
por: Hasson, Carla, et al.
Publicado: (2019)

P1425: SYSTEMATIC INVESTIGATION OF HYDROXYUREA TREATMENT EFFECT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Bhat, Varsha, et al.
Publicado: (2023)

Survival and mortality among users and non-users of hydroxyurea with sickle cell disease
por: de Araujo, Olinda Maria Rodrigues, et al.
Publicado: (2015)

Hydroxyurea-Induced miRNA Expression in Sickle Cell Disease Patients in Africa
por: Mnika, Khuthala, et al.
Publicado: (2019)

Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease
por: Zahran, Asmaa M., et al.
Publicado: (2020)

Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease
por: Barbu, Emilia Alina, et al.
Publicado: (2019)

Hydroxyurea usage awareness among patients with sickle‐cell disease in Saudi Arabia
por: Alsalman, Mortadah, et al.
Publicado: (2021)

Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease
por: Pandey, Akancha, et al.
Publicado: (2023)

Fetal hemoglobin level and nutritional status in patients with sickle cell disease
por: Badawy, Sherif M.
Publicado: (2016)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease
por: Barriteau, Christina M, et al.
Publicado: (2022)

Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea
por: Green, Nancy S., et al.
Publicado: (2013)

Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment
por: Neves, Fabia, et al.
Publicado: (2012)

Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros
por: Santos, Fernanda Kelle de Souza, et al.
Publicado: (2011)

Influence of βS-Globin Haplotypes and Hydroxyurea on Arginase I Levels in Sickle Cell Disease
por: Moreira, J. A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bcbs2mk10sfnq7buckg5t348tm